Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/8/2026, 12:00:00 AM
Merck and Gilead announced on June 8, 2026, the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for KEYTRUDA combined with Trodelvy in non-small cell lung cancer. Internal analysis estimates a moderate negative impact (~5%) due to the failure of a late-stage trial in a major indication, expected.
Korean Translation
머크와 길리어드는 2026년 6월 8일, 비소세포폐암 대상 키트루다와 트로델비 병용 요법에 대한 3상 KEYNOTE-D46/EVOKE-03 연구 중단을 발표함. 내부 분석 결과 주요 적응증에 대한 임상 3상 실패로 약 5%의 부정적 주가 영향이 예상됨.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target is scheduled to report its Q2 2026 financial results on August 19, 2026, with analysts forecasting EPS around $2.21-$2.25. Medium importance is assigned as upcoming earnings are significant catalysts with expected price movement between 5-10%. This event is scheduled.
8/19/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
Second quarter 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release on August 6, 2026, with an estimated ~1% price impact, scheduled.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 financial results after the market closes on August 5, 2026; due to typical earnings volatility, a price impact of at least 5% is expected.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled, with analysts forecasting EPS of approximately $1.66. As this is a significant quarterly update, a medium impact is forecasted.
8/3/2026, 12:00:00 AM
Exxon Mobil Corp (XOM) · Earnings Release
Second-quarter 2026 earnings release scheduled for July 31, 2026. Low importance is based on the expected market reaction to a standard earnings release. Analysts forecast earnings per share of approximately $3.76 estimated.
7/31/2026, 12:00:00 AM